Immunotherapy, the use of the body's immune system to fight cancer, has revolutionized oncology. This article presents a comprehensive guide to understanding the mechanisms, applications, and implications of immunotherapy.
Immunotherapy represents a paradigm shift from traditional cancer treatments. Instead of directly targeting cancer cells, it manipulates the immune system to recognize and destroy them. The two main types are checkpoint inhibitors and CAR-T cell therapy. Checkpoint inhibitors block proteins that prevent immune cells from attacking cancer, while CAR-T cell therapy involves genetically modifying a patient's T cells to target cancer cells.
Immunotherapy has shown efficacy in various cancers, including melanoma, lung, and kidney cancers. It is also being explored in hematological malignancies. However, its effectiveness varies among patients due to factors such as genetic makeup and tumor microenvironment. Biomarkers like PD-L1 expression and tumor mutational burden can predict response to immunotherapy.
Immunotherapy can cause immune-related adverse events (irAEs), which can affect any organ system. Management strategies include corticosteroids and other immunosuppressants. It is essential for physicians to recognize and manage these side effects promptly to prevent severe complications.
The future of immunotherapy lies in combinatorial approaches, personalized medicine, and understanding resistance mechanisms. Ongoing research aims to identify new targets, develop more effective CAR-T cells, and understand why some patients do not respond to treatment.
Immunotherapy has transformed cancer treatment, offering hope to many patients. However, it also poses unique challenges in terms of predicting response, managing side effects, and understanding resistance. As we continue to decode immunotherapy, physicians must stay updated to provide optimal care to their patients.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation